Wanbury Ltd

Wanbury Management Change

Wanbury Limited announced the appointment of ABK & Associates as Cost Auditor and the re-appointment of Mohan Kumar Rayana as Executive Director.

Wanbury Annual General Meeting

Wanbury Limited held its 38th Annual General Meeting on September 24, 2026. Shareholders approved financial statements, director re-appointments, and cost auditor remuneration ratification.

Wanbury Annual General Meeting

Wanbury Limited has issued a notice for its Annual General Meeting scheduled on September 24, 2026, to transact various business resolutions.

Value

₹0.04 Cr

Wanbury Annual General Meeting

Wanbury Limited has scheduled its 38th Annual General Meeting for September 24, 2026. The meeting will address ordinary business, director re-appointments, and cost auditor remuneration.

Wanbury Product Launch

Wanbury Limited received EDQM approval for Rivaroxaban API. The company also obtained USFDA DMF clearances for Paroxetine HCI and Metformin HCI.

Wanbury Results Update

Wanbury reported Q1 FY27 financial results in a press release. The company also completed a Rs. 205 crore debt refinancing, improving its borrowing profile.

Value

₹205.0 Cr

Wanbury Employee Stock Options

Wanbury Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's total paid-up share capital.

Wanbury Management Change

Wanbury Limited has announced the re-appointment of Mr. Mohan Kumar Rayana as an Executive Director, effective August 21, 2026, for a 60-month term.

Wanbury Q1 FY27 Results: Net Profit ₹3.2 Cr, Down 76.3% YoY

Wanbury Ltd reported revenue from operations of ₹165.6 Cr (+1.5% YoY) and net profit of ₹3.2 Cr (-76.3% YoY) for Q1 FY27.

Key figure

Net profit ₹3.2 Cr · -76.3% YoY

Wanbury Board Meeting Date

Wanbury Limited has scheduled a board meeting for August 11, 2026, to consider its unaudited standalone financial results for the quarter ended June 2026.

Wanbury Business Update

Wanbury Limited received a 'No DMF deficiency' letter from the USFDA for multiple ANDAs. This clearance facilitates expansion into the South Korean API market.

Wanbury Business Update

Wanbury Limited announced that the USFDA completed a cGMP inspection at its Tanuku facility, resulting in a Form 483 with six observations.

Wanbury Price Movement Clarification

Wanbury Limited clarified that recent stock price increases are entirely market-driven. The company confirmed no undisclosed material information exists that could impact trading activity.

Wanbury Debt & Borrowing: ₹180 Cr

Wanbury Limited approved the early redemption of Rs. 180 Crore worth of 12.5% Non-Convertible Debentures. This full redemption will be completed before the February 2030 maturity date.

Value

₹180.0 Cr

Wanbury Share Pledge

Wanbury Ltd disclosed Catalyst Trusteeship Ltd, as debenture trustee, released a pledge on 85,20,330 shares on July 6, 2026. The release lowers equity encumbrance.

Wanbury Earnings Call: Key Takeaways

Wanbury achieved a major turnaround in FY26, reporting highest-ever operational EBITDA of ₹108 Cr and 117% PAT growth.

Wanbury Management Change

Wanbury Limited appointed Ernst & Young LLP as Internal Auditors. ABK & Associates were also appointed as Cost Auditors for a 12-month term.

Execution

12 months

Wanbury Merger & Restructuring Worth ₹0.04 Cr

Wanbury approved incorporating subsidiary Wanbury Skin Health Limited with an outlay of ₹0.041 Crore. The company also appointed Ernst & Young LLP as internal auditor.

Value

₹0.04 Cr

Wanbury Share Pledge

Wanbury announced release of pledge on 1,42,03,818 shares, reducing pledged portion to 5.49% with SBM. The company’s borrowing cost will drop below 10% p.a. from 1 July 2026.

Wanbury Business Update

Wanbury Limited's Tanuku site successfully completed Australia's TGA inspection. This regulatory milestone enables the company to export three additional APIs to the Australian market.

Wanbury Product Launch

Wanbury Limited launched new APIs globally through regulatory submissions in Singapore, Malaysia, and Korea. The Patalganga facility also received zero observations from Korea's MFDS.

Wanbury Results Update

Wanbury Limited reported ₹650.3 Crore revenue for FY26, with PAT surging 117% to ₹66.1 Crore. Strong growth was driven by new API launches and improved margins.

Value

₹650.3 Cr

Wanbury Q4 FY26 Results: Net Profit ₹21.7 Cr, Up 6.9% YoY

Wanbury Ltd reported revenue from operations of ₹164.6 Cr (-4.3% YoY) and net profit of ₹21.7 Cr (+6.9% YoY) for Q4 FY26.

Key figure

Net profit ₹21.7 Cr · +6.9% YoY

Wanbury Financial Results

Wanbury Limited reported annual revenue of ₹650.27 Crore and net profit of ₹66.13 Crore for FY26. The results received an unmodified audit opinion, reflecting stable financial performance.

Wanbury Board Meeting Date

Wanbury Limited has rescheduled its board meeting from May 14 to May 29, 2026. The board will then approve quarterly and annual audited financial results.

Wanbury Board Meeting Date

Wanbury Limited has scheduled a board meeting on May 14, 2026, to consider and approve its audited standalone financial results for the year ended March 31, 2026. The company's trading window remains closed until May 16, 2026.

Wanbury Board Meeting Date

Wanbury Limited has scheduled a Board Meeting on May 14, 2026, to consider and approve its audited financial results for the quarter and year ended March 31, 2026. The company's trading window will remain closed until 48 hours after the declaration of the results.

Wanbury Business Update

Wanbury Limited's Patalganga site successfully completed a Korea FDA (MFDS) regulatory inspection with zero observations. The inspection, conducted from April 7 to April 9, 2026, confirms cGMP compliance. This approval follows previous zero-observation inspections by the USFDA and Anvisa, reinforcing the company's manufacturing compliance standards.

Wanbury Legal & Regulatory

Wanbury Limited disclosed a ₹42,480 penalty (including GST) imposed by BSE for a delay in submitting its shareholding pattern for the quarter ended September 2025. The company has since complied and remitted the fine via NEFT on November 27, 2025.

Wanbury Debt & Borrowing: ₹214.4 Cr

Wanbury Ltd has disclosed that it does not qualify as a Large Corporate under SEBI's framework for the financial year. The company reported outstanding borrowings of ₹214.38 Crore as of March 31. This routine regulatory filing confirms the company is not mandated to raise incremental borrowings through debt securities.

Value

₹214.4 Cr